
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc has demonstrated robust financial growth, with total revenue reported at $98.6 million for the second quarter of 2025, reflecting a year-over-year increase of approximately 13%. The strength in MiMedx's wound-care and surgical segments is particularly notable, as the wound portfolio grew by 12% to $64.5 million, while surgical product sales surged by 15% to reach $34.1 million. Additionally, the company has revised its revenue estimate for 2025 to $387.3 million, an increase from the previous projection, indicating confidence in continued operational success and market demand.
Bears say
MiMedx Group Inc has experienced a decline in its gross margin, dropping to approximately 81% from 83% in the previous quarter, primarily attributed to production variances and changes in product mix. The company has committed to a long-term outlook of achieving low double-digit percentage year-over-year revenue growth along with an adjusted EBITDA margin exceeding 20%. However, the potential for adverse changes in reimbursement rates set by CMS poses a significant risk to MiMedx's financial performance and overall business viability.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares